Serinus Biosciences Analysis: $500K Raised
What is Serinus Biosciences?
Serinus Biosciences develops precision medicine drugs targeting drug-resistant cancer by using AI to identify vulnerabilities in resistant tumors.
Employees
6
Founded
2022
Revenue
$0-1M
Business Model
Co-development partnerships and AI-driven drug discovery for pharmaceutical collaborations.
Product Features & Capabilities
- ResCuETM AI platform for identifying druggable vulnerabilities, cost-effective mapping of market opportunities, clinically assayable resistance biomarkers, druggable targets with progressable chemical matter.
How much Serinus Biosciences raised
Pre-Seed - $500,000
September 7, 2022Lead Investor: Y Combinator
Who are the founders of Serinus Biosciences
AY
Adam Yaari
Founder/CEO
MS
Maxwell Sherman
Founder/CTO
Competitors Overview
The main competitors of Serinus Biosciences in the market of cancer drug resistance and AI-driven drug discovery include:
- Owkin: Focuses on using AI to improve drug development and patient outcomes by analyzing patient data and biological information. Their advantage lies in their strong emp
Investors
- Y Combinator
- Illumina Ventures
- Sapir Venture Partners
- Endless Frontier Labs
- Merck Digital
- Phoenix Investment Club
Market Focus
Serinus Biosciences primarily focuses on the biotechnology industry, specifically in the development of drugs to combat cancer drug resistance using artificial intelligence to identify vulnerabilities in resistant tumors.
See something that needs updating? Suggest edits to this profile.